LVTX Stock - LAVA Therapeutics N.V.
Unlock GoAI Insights for LVTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $11.98M | $6.77M | $19.39M | $5.35M | $3.75M |
| Gross Profit | $11.98M | $3.29M | $19.39M | $5.35M | $-11,954,000 |
| Gross Margin | 100.0% | 48.6% | 100.0% | 100.0% | -319.0% |
| Operating Income | $-29,693,000 | $-43,394,000 | $-34,838,000 | $-43,613,000 | $-14,673,000 |
| Net Income | $-25,114,000 | $-41,871,000 | $-31,907,000 | $-42,355,000 | $-15,927,000 |
| Net Margin | -209.6% | -618.6% | -164.5% | -791.7% | -425.1% |
| EPS | $-0.94 | $-1.57 | $-1.23 | $-2.14 | $-39.90 |
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2024 | Leerink Partners | Downgrade | Market Perform | $2← $11 |
| December 11th 2024 | JMP Securities | Downgrade | Market Perform | - |
| October 25th 2022 | H.C. Wainwright | Initiation | Buy | $9 |
Earnings History & Surprises
LVTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 27, 2026 | $-0.22 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.23 | $-0.27 | -17.4% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.37 | $-0.13 | +64.9% | ✓ BEAT |
Q1 2025 | Mar 28, 2025 | $-0.32 | $-0.14 | +56.3% | ✓ BEAT |
Q4 2024 | Dec 10, 2024 | $-0.33 | $-0.46 | -39.4% | ✗ MISS |
Q3 2024 | Aug 20, 2024 | $-0.33 | $-0.31 | +6.1% | ✓ BEAT |
Q2 2024 | May 21, 2024 | $-0.25 | $-0.02 | +92.0% | ✓ BEAT |
Q1 2024 | Mar 20, 2024 | $0.16 | $-0.24 | -250.0% | ✗ MISS |
Q4 2023 | Nov 16, 2023 | $-0.48 | $-0.34 | +29.2% | ✓ BEAT |
Q3 2023 | Aug 22, 2023 | $-0.48 | $-0.48 | 0.0% | = MET |
Q2 2023 | Apr 11, 2023 | $-0.52 | $-0.57 | -9.6% | ✗ MISS |
Q1 2023 | Mar 24, 2023 | $-0.61 | $-0.38 | +37.7% | ✓ BEAT |
Q4 2022 | Nov 16, 2022 | $-0.13 | $0.04 | +130.8% | ✓ BEAT |
Q3 2022 | Sep 13, 2022 | $-0.61 | $-0.31 | +49.2% | ✓ BEAT |
Q2 2022 | May 17, 2022 | $-0.95 | $-0.41 | +56.8% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $-0.38 | $-0.38 | 0.0% | = MET |
Q4 2021 | Nov 15, 2021 | $-0.33 | $-0.27 | +18.2% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q2 2021 | May 20, 2021 | $-0.81 | $-12.27 | -1414.8% | ✗ MISS |
Latest News
XOMA Royalty Completes Acquisition Of LAVA Therapeutics With $1.04 Per Share Cash And CVR, Securing 91.1% Tendered Shares And Initiating Nasdaq Delisting Of LAVA
📈 PositiveLAVA Exceeded Minimum Condition In Tender Offer, Intends To Delist From Nasdaq
➖ NeutralXOMA and LAVA Therapeutics Announce Amendment To Purchase Agreement; LAVA Shareholders Who Tender Their Shares Will Now Receive An Initial Cash Amount Per Share Of $1.04; Amendment To Agreement With LAVA Includes Updated CVR Terms For Tender Offer
➖ NeutralXOMA Royalty And LAVA Therapeutics Announced The Extension Of The Expiration Of The Tender Offer To Purchase All Outstanding Shares Of Common Shares Of LAVA
➖ NeutralFrequently Asked Questions about LVTX
What is LVTX's current stock price?
What is the analyst price target for LVTX?
What sector is LAVA Therapeutics N.V. in?
What is LVTX's market cap?
Does LVTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to LVTX for comparison